Faculty of Physics - University of Bucharest

UNIVERSITY OF BUCHAREST
FACULTY OF PHYSICS

Guest
2024-11-23 18:10

HOME CONFERENCES SEARCH LOGIN NEW USER IMAGES

Conference: Bucharest University Faculty of Physics 2019 Meeting

Section: Optics, Spectroscopy, Plasma and Lasers

Title:

Phenothiazine photoproducts efficacy in treatment of schizoid spectrum diseases

Authors:

Ana-Maria UDREA (1), Tatiana TOZAR (1), Adriana SMARANDACHE (1), Angela STAICU (1), Speranta AVRAM (2), Mihail Lucian PASCU (1)

Affiliation:

1) National Institute for Laser, Plasma and Radiation Physics, Magurele, Ilfov, Romania.

2) Faculty of Biology, University of Bucharest, Bucharest, Romania

E-mail

ana.udrea@inflpr.ro

Keywords:

Phenothiazine; Photoproducts; Antipsychotics; Laser;Dopamine Receptor

Abstract:

Psychiatric pathologies affect millions of people around the world; according to World Health Organization 23 million persons are affected by schizophrenia and 60 million by bipolar disorder. The most effective treatment for those pathologies is represented by antipsychotic and antidepressant medication. Antipsychotics are divided in 2 major classes: typical and atypical antipsychotics (or first and second generation). Phenothiazines are a subclass of typical antipsychotic drugs and include: chlorpromazine, thioridazine, fluphenazine etc.; Phenothiazines act by blocking the activity of dopaminergic receptor D2 (dopamine antagonist). In this study we have tested the binding affinity of some phenothiazines photoproducts, on Dopaminergic D2 receptor using in silico methods. Photoproducts ware obtained after laser irradiation between 1 and 240 minutes at 266 nm, produced by fourth harmonic generation by a Nd:YAG - FHG laser system and identified using FTIR measurements. Moreover, we have predicted the drug-like character of those photoproducts, applying Lipinski drug-like rule.

Acknowledgement:

This work was supported by the Romanian National Authority for Scientific Research and Innovation, CNCS/CCCDI-UEFISCDI, projects number PN-III-P1-1.1-PD-2016-1072 and PN-III-P1-1.1-PCCDI-2017-0728 and NUCLEU Program 16N/08.02.2019.